Comparison of biomarker expression in oral lichen planus and oral lichenoid lesions

• Published in: Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2022-12, Vol.31 (12), p.1327-1334
• Main Authors: Radwan-Oczko, Małgorzata, Lis-Nawara, Anna, Hałoń, Agnieszka, Bar, Julia
• Format: Article
• Language: English
• Subjects: Biomarkers; DNA Topoisomerases, Type I - genetics; DNA Topoisomerases, Type I - metabolism; HSP90 Heat-Shock Proteins - genetics; HSP90 Heat-Shock Proteins - metabolism; Humans; Lichen Planus, Oral - diagnosis; Lichen Planus, Oral - genetics; Lichenoid Eruptions - diagnosis; Lichenoid Eruptions - genetics; Mouth Diseases - diagnosis; Mouth Diseases - genetics; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism
• ISSN: 1899-5276
• DOI: 10.17219/acem/152429

Oral lichen planus (OLP) and oral lichenoid lesions (OLL) comprise a group of oral mucosal disorders that have similar clinical and histological features. To compare the levels of investigated biomarkers in biopsied OLP and OLL, and to determine the pattern of biomarkers, which could be useful for the biological characterization of these 2 disorders. A total of 56 biopsy specimens in 2 groups were analyzed in this study. One group consisted of 25 idiopathic OLP lesions, and the other included 31 OLL from patients treated with antihypertensive and cardiac medications. The expression of protein p53, topoisomerase I (topo I), heat shock protein 90 (HSP90), and E-cadherin was analyzed using immunohistochemistry. The p53 protein expression showed a trend to a positive correlation with topo I expression in the total sample (p = 0.067, R = 0.25). The p53 protein and HSP90 expression was higher in the OLL group compared to the OLP group, but the difference was not statistically significant. No association was found between topo I and E-cadherin expression for either the OLP or OLL group. The findings of this study suggest that the slightly higher protein p53 and HSP90 expression in the OLL group might be caused by the medications used. The slight association between p53 and topo I expression indicates that the cooperation between these proteins might be essential for the growth of OLP/OLL in general. We conclude that the overexpression of p53 protein and high expression of topo I found in both types of lesions might induce their biologically aggressive behavior.